ada 2015 investor & analyst event boston, 7 june 2015 · 2020-04-17 · slide 3 5,05 4,10 3,50...

5,05

4,10

3,50

4,72

11,82 11,82

ADA 2015

Investor & analyst event

Boston, 7 June 2015

Mexico City – part of Cities Changing Diabetes

5,05

4,10

3,50

4,72

11,82 11,82

Forward-looking statements

Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2014 and Form 20-F, both filed with the SEC in February 2015, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

• Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto

• Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures

• Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and

• Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.

Please also refer to the overview of risk factors in ‘Be aware of the risk’ on p 42-43 of the Annual Report 2014 on the company’s website novonordisk.com.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.

Important drug information

• Victoza® (liraglutide 1.2 mg & 1.8 mg) is approved for the management of type 2 diabetes only

• Saxenda® (liraglutide 3 mg) is approved in the US and EU for the treatment of obesity only

ADA 2015 investor and analyst event

5,05

4,10

3,50

4,72

11,82 11,82

Agenda


Time Topic

6.30 pm Welcome – early insights from Saxenda® launch in the US Jesper Brandgaard, CFO

6.35 pm Liraglutide – new data for Saxenda® and Victoza®

Mads Krogsgaard Thomsen, CSO

6.50 pm Faster-acting insulin aspart – controlling postprandial glucose Peter Kurtzhals, SVP Global Research

7.05 pm IDegLira – superior HbA1c reduction with IDegLira compared to insulin glargine Peter Kristensen, SVP Global Development

7.20 pm Discussion and Q&A

5,05

4,10

3,50

4,72

11,82 11,82

0

50

100

150

200

250

16%

43%

41%

Lorcaserin

80% of AOM scripts are still generic

Source: IMS NPA Monthly, Apr 2015

Majority of the anti-obesity medication is generic with new products driving market value expansion

Two latest oral AOM driving branded market expansion

Recent launches increased total AOM market value


0

200

400

600

800

1,000

80%

20%

TRx volume (k)

AOM branded AOM generic

Apr 2015

Apr 2011

0

50

100

150

200

250

300

76%

24%

USD million

AOM branded AOM generic

Apr 2015

Apr 2011

USD million

Naltrexone HCI & bupropion HCI

Phentermine & topiramate

Source: IMS NSP MAT Monthly, Apr 2015 Source: IMS NSP MAT Monthly, Apr 2015

Apr 2015

Apr 2011

5,05

4,10

3,50

4,72

11,82 11,82

8,430

3,989

1,204

816

0

2,000

4,000

6,000

8,000

10,000

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

• Encouraging initial Saxenda® uptake

• Positive early feedback from physicians and patients

• Limited formulary access primarily with prior authorisation

• Expanding formulary access remains a main priority

Note: IMS reporting for new launches may reflect data instability due to small volume and/or supplier reporting Source: IMS NPA TRx, Weekly data

AOM launch uptake Key launch observations

Encouraging early script development for Saxenda®


TRx volume

Weeks from launch

Saxenda®

Lorcaserin

Phentermine & topiramate

Naltrexone HCI & bupropion HCI

5,05

4,10

3,50

4,72

11,82 11,82

Liraglutide – new data for Saxenda® and Victoza®

Mads Krogsgaard Thomsen

EVP & Chief Science Officer


5,05

4,10

3,50

4,72

11,82 11,82

SCALE™ obesity and prediabetes: design of the largest clinical trial conducted within obesity

Note: *Treated or untreated hypertension or dyslipidaemia according to ATP-III; **Treatment ends at week 68 for the non-prediabetic population and is proceeded by an off-treatment follow-up period of 2 weeks. ClinicalTrials.gov. Identifier: NCT01272219 Source: Wilding et al. ADA 2015. Poster number 2229


Screening

0.6 mg 1.2 mg

1.8 mg

2.4 mg

Liraglutide 3 mg

Placebo

Dose escalation

Liraglutide 3 mg

Placebo

Liraglutide 3 mg

Placebo

Non- prediabetic

Prediabetic

0.6 mg

1.2 mg 1.8 mg

2.4 mg Observational follow-up

Follow-up

0 4 160 Week −2 172 70 68 56

3,731 people with:

• BMI: ≥30 or (≥27+ comorbidities*)

• Stable body

weight &

preceding failed

dietary effort

Randomisation: 2:1 EOTT EOS** EOS

Re-randomisation: 1:1

Lifestyle intervention: -500 kcal/day hypo caloric diet + increased physical activity

5,05

4,10

3,50

4,72

11,82 11,82

Number of participants in different categories for Saxenda® and placebo after 56 weeks

Reversal of prediabetes in early responders who completed 56 weeks of treatment

The majority of early Saxenda® responders lost ≥5% or >10% weight and reversed prediabetes in SCALE™ trial

1 Participants losing ≥4% body weight at week 16 with prediabetes and completing 56 weeks treatment * Percentage of people with prediabetes; ** Percentage of completed early responders

Source: Wilding et al. ADA 2015. Poster number 2229 Source: Wilding et al. ADA 2015. Poster number 2229

Saxenda® Placebo

2,487

1,528

905 (59%*)

765 (85%**)

431 (48%**)

1,244

757

165 (22%*)

114 (69%**)

55 (33%**)

Saxenda® Placebo

Randomised

With prediabetes

Completed early responders1

Completed early responders with ≥5% weight loss

Completed early responders with >10% weight loss


76.9 82.8

46.5

58.2

0

20

40

60

80

100

Pro

po

rti

on

of

parti

cip

an

ts (

%)

Participants achieving ≥5% weight loss

Participants achieving >10% weight loss

5,05

4,10

3,50

4,72

11,82 11,82

SCALE™ obesity and prediabetes: 3 years trial design

Note: * Treated or untreated hypertension or dyslipidaemia according to ATP-III; **Treatment ends at week 68 for the non-prediabetic population and is proceeded by an off-treatment follow-up period of 2 weeks. ClinicalTrials.gov. Identifier: NCT01272219 Source: Pi-Sunyer et al. AACE. 2014. Abstract number: 700


Screening

0.6 mg 1.2 mg

1.8 mg

2.4 mg

Liraglutide 3 mg

Placebo

Dose escalation

Liraglutide 3 mg

Placebo

Liraglutide 3 mg

Placebo

Non- prediabetic

Prediabetic

0.6 mg

1.2 mg 1.8 mg

2.4 mg Observational follow-up

Follow-up

0 4 160 Week −2 172 70 68 56

3,731 people with:

• BMI: ≥30 or (≥27+ comorbidities*)

• Stable body

weight &

preceding failed

dietary effort

Randomisation: 2:1 EOTT EOS** EOS

Re-randomisation: 1:1

Lifestyle intervention: -500 kcal/day hypo caloric diet + increased physical activity

5,05

4,10

3,50

4,72

11,82 11,82

• Approximately 80% reduced risk of developing T2D for people treated with Saxenda®3

• At 160-week, completion rate of 53% and 45% for Saxenda® and placebo respectively

• Saxenda® appeared to have a safe and well tolerated profile and most frequently reported adverse events were gastrointestinal in nature

1 p<0.0001. 2 p<0.0001 Source: Pi-Sunyer et al. AACE. 2014. Abstract number: 700; Novo Nordisk data on file (NN8022-1839)

Sustained weight loss with Saxenda® SCALETM

obesity and prediabetes trial Saxenda® effect on emerging type 2 diabetes

After three years of treatment Saxenda® shows sustained weight loss and reduced risk of type 2 diabetes vs placebo in SCALE™ trial

3 p<0.0001 Source: Novo Nordisk data on file (NN8022-1839)


Saxenda® (placebo) 56 weeks1

Saxenda®

(placebo) 160 weeks2

Mean weight reduction

8% (3%) 6% (2%)

Proportion achieving 5% weight reduction

63% (27%) 50% (23%)

Proportion achieving 10% weight reduction

33% (11%) 24% (9%)

5,05

4,10

3,50

4,72

11,82 11,82

89

90

91

92

93

94

95

96

97

98

99

100

0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168

Time to onset of T2D up to 160 weeks of treatment estimated survival time

Note: Time of onset of T2D occurs between first of two required registrations of elevated HbA1c, FPG or 2 hour oral glucose tolerance test plasma glucose, and the diabetes assessment visit prior to first registration. The estimated survival time is based on an analysis of time to onset of T2D analysed in a Weibull model including treatment, gender and BMI stratification factor as fixed factors and baseline FPG as covariate. Output presents data for subjects with prediabetes at baseline and includes 6 subjects who did not have prediabets at baseline, but participated in the extension period of the trial. Source: Weibull analysis, FAS

Saxenda® treatment increases time to onset of type 2 diabetes vs placebo in 3-years SCALETM trial – For each 14 patients treated with Saxenda® for three years one case of diabetes is prevented


Time since randomisation (weeks)

Su

bje

cts

no

t d

iag

no

sed

w

ith

TD

2 (

%)

Saxenda® Placebo

factor=2.6

0

5,05

4,10

3,50

4,72

11,82 11,82

• Metformin can be used safely

• SUs should be used with caution due to inherent risk of

hypoglycaemia

• GLP-1s might be associated with a low risk of hypoglycaemia

in addition to their potent effect on glycaemic control and

bodyweight

Source: The world factbook on www.cia.gov/library/publications/the-world-factbook; The Future Global Muslim Population Projections for 2010-2030. Pew Research Center; IDF Diabetes Atlas 2014

Around 100 million Muslims estimated to have type 2 diabetes ADA recommendations during Ramadan

Practicing muslims with type 2 diabetes could benefit from GLP-1 during Ramadan but limited clinical data has existed

Source: Al-Arouj M et al. Diabetes Care 2010;33(8):1895–1902


Muslim population: 1.7 billion

Adults with T2D: 387 million

Global population: 7.2 billion

5,05

4,10

3,50

4,72

11,82 11,82

Overall results: • Victoza® was associated with a significantly larger reduction

in HbA1c and body weight compared with SU1

• A significantly lower risk of confirmed hypoglycaemia was observed with Victoza® vs SU2

During Ramadan: • Victoza® was associated with a similar reduction in

fructosamine compared with SU

• Numerically fewer hypoglycaemic episodes were seen with Victoza® vs SU despite better glycaemic control

1 Inclusion criteria: Type 2 diabetes, BMI 20 kg/m2, HbA1c 7–10%, on metformin 1000 mg/day and SU 90 days and intent to fast during Ramadan * Ramadan lasts between 29-30 days

Source: Azar et al. ADA 2015. Poster number 1121

Trial design Key trial results

Randomised clinical trial investigating ability of Victoza® to improve glycaemic control during Ramadan

1 p<0.001; 2 p=0.0027 Fructosamine: glycated serum protein reflecting glycaemic control for the previous 2−3 weeks Source: Azar et al. ADA 2015. Poster number 1121


SU + metformin

Victoza® + metformin

Dose escalation

341 people with type 2 diabetes1

0 -2

Screening Treatment

maintenance Ramadan

Post Ramadan

3-4 6-9 4* 4* Week

5,05

4,10

3,50

4,72

11,82 11,82

Faster-acting insulin aspart – controlling postprandial

glucose Peter Kurtzhals

SVP Global Research


5,05

4,10

3,50

4,72

11,82 11,82

Sustained Insulin profile (basal)

The aim of insulin therapy is to recreate normal blood insulin profile

Faster-acting insulin approaching physiological insulin profile even further

Unmet medical need for a faster-acting insulin approaching physiological insulin profile and with better pump profile

Source: Polonsky KS et al. N Engl J Med 1988;318:1231–1239 * Schematic representation


Time (h)

In

su

lin

acti

on

(at

mealt

ime)

*

Human insulin

Faster-acting insulin

Fast acting insulin

Pancreas release

6:00 0

10

20

30

40

50

60

70

10:00 14:00 18:00

Insulin (mU/L)

22:00 2:00 6:00

Short-lived, rapidly generated meal-related peaks (prandial)

Time of day

Breakfast Lunch Dinner

5,05

4,10

3,50

4,72

11,82 11,82

Elements influencing postprandial glucose (PPG)

In diabetes, PPG depends on early insulin appearance and action on the liver and peripheral tissues after a meal


Process 2

Process 3

Add text

Action on the liver Peripheral tissues after a meal

Early insulin appearance

5,05

4,10

3,50

4,72

11,82 11,82

75% 62%

25% 38%

0%

20%

40%

60%

80%

100%

Healthy Type 2 Diabetes

Hepatic glucose release drives overall higher PPG release in T2D patients

Hepatic glucose production accounts for larger part of PPG in T2D vs healthy people

Need for a faster-acting insulin to reduce hepatic glucose production around meal

Source: Woerle HJ et al. Am J Physiol Endocrinol Metab 2006;290:E67–E77 Source: Woerle HJ et al. Am J Physiol Endocrinol Metab 2006;290:E67–E77


59 61

19

37

0

20

40

60

80

100

120

Healthy Type 2 diabetes

PPG release over 6-hours (g)

Meal-related glucose Hepatic glucose Meal-related glucose Hepatic glucose

5,05

4,10

3,50

4,72

11,82 11,82

-2

0

2

4

6

8

-60 0 60 120 180 240

Faster-acting insulin aspart shows higher plasma glucose reduction in meal test

Greater glucose-lowering after meal with faster-acting insulin aspart

Faster-acting insulin aspart shows higher glucose reduction in phase 1 trial

Source: Bode et al ADA 2015. Poster number: 994

* p<0.05

Source: Bode et al ADA 2015. Poster number: 994


Faster-acting insulin aspart vs insulin aspart

Change in plasma glucose following meal test after 14 days

ΔPGav,0–1h, mmol/L –0.50 [–1.07; 0.07]

ΔPGav,0–2h, mmol/L –0.99* [–1.95; –0.03]

Baselin

e a

dju

ste

d p

lasm

a

glu

co

se (

mm

ol/

L)

Nominal time (min)

Insulin aspart Faster-acting insulin aspart

5,05

4,10

3,50

4,72

11,82 11,82

• Greater improvement of HbA1c with mealtime faster-acting insulin aspart compared to NovoRapid®

• Similar HbA1c improvement with faster-acting insulin aspart when dosed post-meal and NovoRapid®

• Statistically larger improvements in 1- and 2-hour PPG increments with meal-time faster-acting insulin aspart

• Similar overall rate of hypoglycaemia for all treatment groups, with a higher rate within first hour after meal with faster-acting insulin aspart if dosed at mealtime

• Previously reported safety and tolerability profiles of insulin aspart confirmed

1 Inclusion criteria: Type 1 diabetes, optimised on Levemir®. 1,143 people randomised

MT: Mealtime; PM: Post-meal Source: Novo Nordisk data on file (NN1218-3852 T1D)

onset® 1 trial design Headline results

Faster-acting insulin aspart shows additional improvement of HbA1c vs NovoRapid® in phase 3 trial onset® 1


Faster-acting insulin aspart

(PM)

Faster-acting insulin aspart (MT)

NovoRapid® (MT)

52 weeks

26

-8 0 Run-in

1,290 people with type 1 diabetes1

Source: Novo Nordisk data on file (NN1218-3852 T1D)

5,05

4,10

3,50

4,72

11,82 11,82

• Similar reduction of HbA1c in both treatment groups

• Statistically larger improvement in 1-hour PPG increment with faster-acting insulin aspart and numerically larger reduction for 2-hour PPG increment

• Similar overall rate of hypoglycaemia, with a higher rate of hypoglycaemia for faster-acting insulin aspart within first two hours after meal

• Previously reported safety and tolerability profiles of insulin aspart confirmed

1 Inclusion criteria: Type 2 diabetes, optimised on basal insulin and OAD; HbA1c of 7.5-9.5%. 689 people randomised

MT: Mealtime Source: Novo Nordisk data on file (NN1218-3853 T2D)

onset® 2 trial design Headline results

Faster-acting insulin aspart shows larger improvement in 1-hour postprandial glucose vs NovoRapid® in phase 3 trial



Faster-acting insulin aspart (MT)

NovoRapid® (MT)

26 weeks

-8 0 Run-in

Source: Novo Nordisk data on file (NN1218-3853 T2D)

5,05

4,10

3,50

4,72

11,82 11,82

IDegLira – superior HbA1c reduction with IDegLira

compared to insulin glargine


Peter Kristensen

SVP Global Development

5,05

4,10

3,50

4,72

11,82 11,82

Remaining IDegLira phase 3 data shown at this year’s ADA

Phase 3a trials Phase 3b trials

2011 2012 2013 2014

DUAL™ I: IDegLira vs individual components, 26 weeks, n=1,660

26-week extension

DUAL™ II: IDegLira vs IDeg, n=400

DUAL™ III: Switch from GLP-1 therapy, 26 weeks, n=429

DUAL™ IV: Add-on to SU, 26 weeks, n=435

DUAL™ V: IDegLira vs IGlar, 26 weeks, n=554

Note: Timing of trials as listed on www.clinicaltrials.gov excl. data analysis


Oral: ADA 2014

Oral: ADA 2014

Oral: ADA 2015

Data presentation

Poster: ADA 2015

Poster: ADA 2015

5,05

4,10

3,50

4,72

11,82 11,82

Trial design Baseline characteristics

DUAL™ V phase 3 trial investigating IDegLira vs insulin glargine in people with type 2 diabetes

1 Inclusion criteria: Type 2 diabetes, insulin glargine (20–50 units) + metformin, 7%≤ HbA1c ≤10%, Age ≥18 years, BMI ≤40 kg/m2 Note: IDegLira starting dose: 16 dose steps; max dose: 50 dose steps. Insulin glargine starting dose: pre-trial dose; max dose: none Source: Buse et al. ADA 2015. Oral number 166 Source: Buse et al. ADA 2015. Oral number 166

IDegLira IGlar

Mean age (years) 58.4 59.1

Mean diabetes duration (years)

11.6 11.3

Mean BMI (kg/m2) 31.7 31.7

Mean HbA1c 8.4% 8.2%

Mean FPG (mmol/L) 8.9 8.9

Mean pre-trial insulin glargine dose

31 32

IGlar + metformin

IDegLira + metformin

26 weeks


0 -2

Run-in open label, 1:1 randomisation


5,05

4,10

3,50

4,72

11,82 11,82

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

90

100

110

120

130

140

150

160

170

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

Statistically significantly higher reduction of HbA1c with IDegLira vs IGlar

Both patient groups achieved similar FBG at the end of trial

IDegLira associated with superior HbA1c reduction compared with insulin glargine in DUAL™ V

* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar Source: Buse et al. ADA 2015. Oral number 166

Note: Mean observed values FAS and LOCF imputed data Source: Buse et al. ADA 2015. Oral number 166


7.1% ∆: -1.13

HbA1c (%)

0.0

6.6% ∆: −1.81

* FP

G (

mm

ol/

L)

Time (weeks) 26 0

IDegLira IGlar IDegLira IGlar

0.0

Time (weeks) 26 0

6.1 mmol/L (110.2 mg/dL)

6.1 mmol/L (109.5 mg/dL)

0

FP

G (

mg

/d

L)

5,05

4,10

3,50

4,72

11,82 11,82

-2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

0

10

20

30

40

50

60

70

Time (weeks)

Statistically significant mean weight difference of -3.2kg for IDegLira vs IGlar

Patients treated with IDegLira in DUAL™ V require lower insulin dose and achieve weight loss vs insulin glargine

* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar Source: Buse et al. ADA 2015. Oral number 166

* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF Source: Buse et al. ADA 2015. Oral number 166

Insulin dose units

kg

Statistically significantly fewer insulin units used by patients treated with IDegLira vs IGlar

66 units

41 units

*

89.1 kg ∆: +1.8

86.9 kg ∆: −1.4

*


Time (weeks) 26 0 26 0


5,05

4,10

3,50

4,72

11,82 11,82

Statistically significantly lower rate of confirmed hypoglycaemia with IDegLira vs IGlar

Statistically significantly lower rate of confirmed nocturnal hypoglycaemia with IDegLira vs IGlar

IDegLira associated with lower rates of confirmed and nocturnal hypoglycaemia vs insulin glargine in DUAL™ V

* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar. Confirmed hypoglycaemia was defined as severe or <56 mg/dL Source: Buse et al. ADA 2015. Oral number 166

* p<0.001; mean observed values FAS and LOCF imputed data; treatment difference ANCOVA analysis; ∆ values observed LOCF. No maximum dose for IGlar. Confirmed severe or <56 mg/dL; Nocturnal between 00:01–05:59 (both inclusive) Source: Buse et al. ADA 2015. Oral number 166

0.0

0.5

1.0

1.5

2.0

2.5

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

Number of episodes per subject

Number of episodes per subject

*

*


Time (weeks) Time (weeks)

Treatment ratio: 0.43

Treatment ratio: 0.17

26 0 26 0


5,05

4,10

3,50

4,72

11,82 11,82

71.6

54.3 50.0 38.8

47.0

29.4 19.7

12.2 0

10

20

30

40

50

60

70

80

Few patients experience nausea when treated with IDegLira

Proportion of subjects achieving HbA1c <7% and composite endpoints with IDegLira vs IGlar

More patients treated with IDegLira achieve treatment targets vs insulin glargine in DUAL™ V

Source: Buse et al. ADA 2015. Oral number 166. Data are from safety analysis set

* p<0.001. Responders are based on FAS and LOCF inputed data Source: Buse et al. ADA 2015. Oral number 166


Proportions of subjects (%)

IDegLira IGlar

HbA1c<7% HbA1c<7% w/o weight gain

HbA1c<7% w/o hypoglycaemia

HbA1c<7% w/o hypoglycaemia & weight gain

*

*

*

*

0

2

4

6

8

10

IDegLira IGlar Frequency (%)

Time (weeks) 26 0

5,05

4,10

3,50

4,72

11,82 11,82

Concluding remarks


3-year treatment with Saxenda® reduces risk of type 2 diabetes by 80% compared with placebo in SCALE ™ trial

Encouraging initial uptake of Saxenda® in the US but formulary access remains the key challenge

Victoza® has the ability to improve glycaemic control during Ramadan as documented in clinical trial

Faster-acting insulin aspart shows improved glycaemic control vs NovoRapid® in phase 3 trials

IDegLira shows superiority vs IGlar in DUAL™ V with a HbA1c reduction of 1.8% and a 3.2 kg weight benefit

5,05

4,10

3,50

4,72

11,82 11,82

Jesper Brandgaard, EVP & CFO

Mads Krogsgaard Thomsen, EVP & CSO

Peter Kurtzhals, SVP Global Research

Peter Kristensen, SVP Global Development


5,05

4,10

3,50

4,72

11,82 11,82

Share information Investor Relations contacts

Investor contact information

Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For further company information, visit Novo Nordisk on the internet at: novonordisk.com

Kasper Roseeuw Poulsen +45 3079 4303 [email protected]

Daniel Bohsen +45 3079 6376 [email protected]

Melanie Raouzeos +45 3075 3479 [email protected]

In North America:

Frank Daniel Mersebach

+1 609 235 8567

[email protected]

Novo Nordisk A/S Investor Relations Novo Allé, DK-2880 Bagsværd

06 Aug 2015 Financial statement for the first six months of 2015

29 Oct 2015 Financial statement for the first nine months of 2015

03 Feb 2016 Financial statement for 2015

Upcoming events


mailto:[email protected]




5,05

4,10

3,50

4,72

11,82 11,82

Appendix – Glossary


Abbreviation Meaning Abbreviation Meaning Abbreviation Meaning

ADA American Diabetes Association FAS Fasting plasma glucose LOCF Last observation carried forward

ANCOVA Analysis of covariance GIR Glucose infusion rate PG Plasma glucose

AOM Anti-obesity medication GLP-1 Glucagon-like peptide-1 PPG Postprandial glucose

BMI Body mass index (kg/m2) HbA1c Glycated haemoglobin A1c TRx Total prescriptions

EOS End of study IAsp Insulin aspart T2D Type 2 diabetes

EOTT End of treatment IDeg Insulin degludec SU Sulfonylurea

FAS Full analysis set IGlar Insulin glargine

ada 2015 investor & analyst event boston, 7 june 2015 · 2020-04-17 · slide 3 5,05 4,10 3,50...

Documents